MINERALYS THERAPEUTICS, INC. (MLYS) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$246.03M*; Operating income -$246.04M; Depreciation and amortization $5.00K*.
- 2026-03-31: Basis Reported; EBITDA -$45.33M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$38.27M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$41.12M*; Operating income -$41.13M; Depreciation and amortization $15.00K*.
Complete source-backed ebitda history.
- Available history
- 2023-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$246.03M* | -$246.04M | $5.00K* | (m) | (m) | (m) | -$32.56M* | (m) | $221.38M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$45.33M | (m) | (m) | (m) | (m) | (m) | -$39.47M | (m) | $24.36M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$38.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$41.12M* | -$41.13M | $15.00K* | (m) | (m) | (m) | -$28.87M* | (m) | $31.45M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$46.73M* | -$46.75M | $16.00K* | (m) | (m) | (m) | -$30.17M* | (m) | $38.28M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$44.43M | (m) | (m) | (m) | (m) | (m) | -$45.49M | (m) | $37.88M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$51.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$60.09M* | -$60.11M | $11.00K* | (m) | (m) | (m) | -$50.19M* | (m) | $53.98M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$45.16M* | -$45.17M | $9.00K* | (m) | (m) | (m) | -$30.15M* | (m) | $39.27M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$35.35M | (m) | (m) | (m) | (m) | (m) | -$19.14M | (m) | $30.75M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$27.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$26.27M* | -$26.27M | $0.00* | (m) | (m) | (m) | -$19.03M* | (m) | $22.50M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$15.73M* | -$15.73M | $0.00* | (m) | (m) | (m) | -$20.39M* | (m) | $11.88M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$14.94M | (m) | (m) | (m) | (m) | (m) | -$12.78M | (m) | $12.29M | (m) | (m) |
|---|
| 2022-09-30 | Reported | (m) | -$7.42M | (m) | (m) | (m) | (m) | -$6.99M* | (m) | $6.06M | (m) | (m) |
|---|
| 2022-06-30 | Reported | (m) | -$6.48M | (m) | (m) | (m) | (m) | -$5.47M* | (m) | $5.59M | (m) | (m) |
|---|
| 2022-03-31 | Reported | (m) | -$7.57M | (m) | (m) | (m) | (m) | -$6.58M | (m) | $6.78M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$170.55M | (m) | (m) | (m) | (m) | (m) | -$142.42M | (m) | $132.01M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$192.36M | (m) | (m) | (m) | (m) | (m) | -$166.31M | (m) | $168.58M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$84.66M | (m) | (m) | (m) | (m) | (m) | -$81.17M | (m) | $70.36M | (m) | (m) |
|---|
| 2022-12-31 | Reported | (m) | -$31.48M | (m) | (m) | (m) | (m) | -$29.22M | (m) | $26.25M | (m) | (m) |
|---|